title: Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma.
abstract: Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-expressing T cells to mediate anti-tumor activity as well as induce endogeneous antitumoral immune responses.
authors: Abramson Cancer Center; Department of Medicine; Division of Hematology-Oncology; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA USA.
authors: Gregory L
authors: GL
authors: Beatty
keywords: T cell; adoptive cell therapy; cancer; chimeric antigen receptor; epitope spreading; immunosurveillance; pancreas